Clincosm LogoSign in Get a demo

Pre-Exposure Prophylaxis Dosing in Pregnancy to Optimize HIV Prevention (PREP-P)

Sponsor
Johns Hopkins University (Other)
Overall Status
Withdrawn
CT.gov ID
NCT03834909
Collaborator
(none)
0
Enrollment
2
Arms
72
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

This trial is a prospective, multi-center, randomized comparison study of 2 Pre-Exposure Prophylaxis (PrEP) pharmacokinetic (PK) dosing regimens from 1st trimester through 12 weeks following delivery (postpartum) to achieve study objectives which include PK, safety monitoring for maternal and fetal/infant safety signals, and adherence.

Condition or Disease Intervention/Treatment Phase
  • Drug: Standard dose Truvada®
  • Drug: Pregnancy-adjusted dose Truvada®
 Phase 1

Detailed Description

Study participants will be randomized to one of two parallel study arms, involving dosing of tenofovir disoproxil sodium/emtricitabine (TDF/FTC). The investigators will be recruiting and enrolling in the late 1st (preferred) and 2nd trimesters of pregnancy to capture the changes in kidney function and blood flow through the kidneys that appear to start in the late 1st trimester and are most significant in the 2nd and 3rd trimesters of pregnancy. Given the unknown time frame for the return to pre-pregnancy physiologic state and the increased risk of HIV acquisition postpartum, participants will be continued on study dose PrEP until after participants' 1-3 week postpartum visit, after which all participants will be dispensed standard dose PrEP. A 6-12 week postpartum study visit will also be performed to evaluate the timing of return to non-pregnant plasma drug levels during the postpartum period.

PK Sampling. Primary PK data will be derived from up to 7 study visits with PK sampling, including two PK visits in each trimester and postpartum. All PK visits sample blood before an observed PrEP dose. .

Safety Sampling. Maternal safety assessments will continue until 6 months postpartum. Fetal evaluation includes non-invasive limited ultrasound (US) and biophysical profiles (BPP) at study visits and 2nd and 3rd trimester interval growth US, and chart review of all before birth assessments. At birth, the investigators will obtain cord blood plasma to assess for mitochondrial function. Infant safety assessments will continue until 1 year of life. Infants will undergo swaddled Dual-energy X-ray absorptiometry (DXA) scans (without sedation) at 3-6, 24-28, and 50-54 weeks of age. The investigators will assess kidney function by blood sample at 3-6 weeks of life and repeated at 24-28 weeks.

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
The investigators will randomly allocate participants in a 1:1 ratio to two parallel study arms (based on a computer generated randomization scheme).The investigators will randomly allocate participants in a 1:1 ratio to two parallel study arms (based on a computer generated randomization scheme).
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Correcting Pre-Exposure Prophylaxis (PrEP) Dosing and Adherence Benchmarks in Pregnancy to Optimize HIV Prevention (PrEP-P): A Randomized Comparative Pharmacokinetic Trial
Anticipated Study Start Date :
Apr 1, 2022
Anticipated Primary Completion Date :
Sep 1, 2027
Anticipated Study Completion Date :
Apr 1, 2028

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Standard Dose Truvada®

Standard Dose Truvada® - Tenofovir disoproxil fumarate (TDF) 300 mg/Emtricitabine (FTC) 200 mg fixed dose combination (Truvada®), one tablet each day

Drug: Standard dose Truvada®
TDF/FTC fixed dose combination, 300 mg TDF/200 mg FTC, one tablet each day
Other Names:
  • Tenofovir Disoproxil Fumarate/Emtricitabine
  • TDF/FTC

    		•
    Experimental: Pregnancy-Adjusted Truvada®

    Pregnancy-Adjusted dose Truvada® - Tenofovir disoproxil fumarate (TDF) 300 mg/Emtricitabine (FTC) 200 mg fixed dose combination (Truvada®), two tablets each day

    Drug: Pregnancy-adjusted dose Truvada®
    TDF/FTC fixed dose combination, 300 mg TDF/200 mg FTC, two tablets each day
    Other Names:
  • Tenofovir Disoproxil Fumarate/Emtricitabine
  • TDF/FTC

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Plasma Tenofovir (TFV) Concentration [36 weeks]

      Plasma Tenofovir (TFV) Concentration in nanograms per milliliter (ng/mL)

    2. Plasma Emtricitabine (FTC) Concentration [36 weeks]

      Plasma Emtricitabine (FTC) Concentration in nanograms per milliliter (ng/mL)

    3. Peripheral Blood Mononuclear Cell (PBMC) TFV-Diphosphate (TFV-DP)Concentration [36 weeks]

      PBMC TFV-DP concentration in femtomoles/million cells (fmol/10E6 cells)

    4. Peripheral Blood Mononuclear Cell (PBMC) FTC-Triphosphate (FTC-TP)Concentration [36 weeks]

      PBMC TFV-DP concentration in femtomoles/million cells (fmol/10E6 cells)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    • age 18 years or older

    • Able to speak English, French, or Spanish

    • Able and willing to provide written informed consent

    • Viable first (preferable) or second trimester intrauterine pregnancy

    • Creatinine clearance >70 ml/min

    • Negative HIV test and no signs/symptoms of acute HIV infection,

    • Documented negative hepatitis B virus status.

    Exclusion Criteria:
    • HIV positive at any time in the study. All neonates of mothers participating in the trial will be recruited, regardless of gestational age at delivery or congenital anomalies/comorbidities.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Johns Hopkins University

    Investigators

    • Principal Investigator: Craig Hendrix, MD, Johns Hopkins University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Johns Hopkins University
    ClinicalTrials.gov Identifier:
    NCT03834909
    Other Study ID Numbers:
      First Posted:
      Feb 8, 2019
      Last Update Posted:
      Apr 6, 2022
      Last Verified:
      Mar 1, 2021
      Individual Participant Data (IPD) Sharing Statement:
      No
      Plan to Share IPD:
      No
      Studies a U.S. FDA-regulated Drug Product:
      Yes
      Studies a U.S. FDA-regulated Device Product:
      No
      Keywords provided by Johns Hopkins University
      HIV Prevention
      Healthy Volunteer
      Additional relevant MeSH terms:
      Tenofovir
      Emtricitabine
      Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination

      Study Results

      No Results Posted as of Apr 6, 2022